%PDF-1.4
%
36 0 obj
<>
endobj
33 0 obj
<>
endobj
105 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-07-29T18:27:20Z
2024-03-28T22:09:02-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T22:09:02-07:00
application/pdf
Heather
2002-1086.sept
uuid:70a53761-1dd2-11b2-0a00-e908275d6100
uuid:70a53764-1dd2-11b2-0a00-aa0000000000
endstream
endobj
22 0 obj
<>
endobj
23 0 obj
<>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 12 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 14 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 16 0 R/Type/Page>>
endobj
115 0 obj
[120 0 R]
endobj
116 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 0 k
/GS1 gs
420 777 137 -27 re
f*
0 0 0 1 K
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:9)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(1996)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61 351.3293 Tm
[(4.)-875 (Peters-Golden M, )18 (W)40 (ise RA, Hochber)18 (g M, et al. Incidence of lung)]TJ
1.675 -1.25 Td
[(cancer in systemic sclerosis. J Rheumatol 1985;12:1)37 (136-9.)]TJ
-1.675 -1.25 Td
[(5.)-875 (Roumm )55 (AD, Medsger )18 (T)80 (A. Cancer and systemic sclerosis: an)]TJ
1.675 -1.25 Td
[(epidemiological study)65 (. )55 (Arthritis Rheum 1985;28:1336-40.)]TJ
-1.675 -1.25 Td
[(6.)-875 (Abu Shakra M, Guillemin F)80 (, Lee P)111 (. Cancer in systemic sclerosis.)]TJ
1.675 -1.25 Td
(Arthritis Rheum 1993;36:460-4.)Tj
-1.675 -1.25 Td
[(7.)-875 (Rosenthal )55 (AK, McLaughlin JK, Gridley G, Nyren O. Incidence of)]TJ
1.675 -1.25 Td
(cancer among patients with systemic sclerosis. Cancer)Tj
0 Tc 0 Tw 0 -1.25 TD
(1995;76:910-4.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875 (Gruber BL, Miller F)80 (, Kauf)18 (fman LD. Simultaneous onset of)]TJ
1.675 -1.25 Td
[(systemic sclerosis \(scleroderma\) and lung cancer: )55 (A)-220 (case report and)]TJ
T*
[(histologic analysis of fibrogenic peptides. )55 (Am J Med )]TJ
0 Tc 0 Tw T*
(1992;92:705-8.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875 (Sakkas LI, Moore DF)80 (, )55 (Akritidis NC. Cancer in families with)]TJ
1.675 -1.25 Td
[(systemic sclerosis. )55 (Am J Med Sci 1995;310:223-5.)]TJ
-2.175 -1.25 Td
[(10.)-875 (W)80 (einer ES, Earnshaw )18 (WC, Senecal JL, Bordwell B, Johnson P)111 (,)]TJ
2.175 -1.25 Td
[(Rothfield NF)80 (. Clinical associations of anticentromere antibodies)]TJ
T*
[(and antibodies to topoisomerase I: a study of 355 patients. )55 (Arthritis)]TJ
0 Tc T*
(Rheum 1988;31:378-85.)Tj
-0.00011 Tc 30.8619 22.5 Td
[(1)37 (1.)-875 (Rothfield N, Kurtzman S, )18 (V)111 (azques-Abad D, Charron C, Daniels L,)]TJ
2.1381 -1.25 Td
[(Greenber)18 (g B. )55 (Association of anti-topoisomerase I with cancer)]TJ
T*
[([letter]. )55 (Arthritis Rheum 1992;35:724.)]TJ
-2.175 -1.25 Td
[(12.)-875 (Higuchi M, Horiuchi )18 (T)74 (, Ishibashi N, )37 (Y)100 (oshizawa S, Niho )37 (Y)129 (,)]TJ
2.175 -1.25 Td
[(Nagasawa K. )55 (Anticentromere antibody as a risk factor for cancer in)]TJ
T*
(patients with systemic sclerosis. Clin Rheumatol 2000;19:123-6.)Tj
-2.175 -1.25 Td
[(13.)-875 (Kyndt X, Hebbar M, Queyrel )18 (V)129 (, Hachulla E, Hatron PY)129 (, Devulder)]TJ
2.175 -1.25 Td
[(B. Systemic scleroderma and cancer)55 (. Search for predictive factors)]TJ
T*
(of cancer in 123 patients with scleroderma. Rev Med Interne)Tj
0 Tc 0 Tw T*
(1997;18:528-32.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14.)-875 (Masi )55 (A)111 (T)74 (, Rodnan GP)111 (, Medsger )18 (T)80 (A)-220 (Jr)40 (, et al. Subcommittee for)]TJ
2.175 -1.25 Td
[(Scleroderma Criteria of the )55 (American Rheumatism )55 (Association)]TJ
T*
[(Diagnostic and )18 (Therapeutic Criteria Committee. Preliminary)]TJ
T*
(criteria for the classification of systemic sclerosis \(scleroderma\).)Tj
T*
(Arthritis Rheum 1980;23:581-90.)Tj
ET
0 0 0 0 k
408 770 150 -25 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
0 Tc 8 0 0 8 128 712.5293 Tm
[(T)92 (able 2. )]TJ
/T1_1 1 Tf
-0.00011 Tc 3.7059 0 Td
(Autoantibodies and cancer in SSc patients. Data are given as percentages\
.)Tj
-3.7059 -2.5 Td
[(Autoantibody Studies)-5731 (SSc + Cancer)40 (, n = 73*)-2446 (SSc, No Cancer)40 (, n = 150)-4146 (p)]TJ
0 Tw 0 -2.5 TD
[(ANA)-220 (\(+\))-14885 (86)-10375 (90.60)-7400 (0.35)]TJ
0.02499 Tw 0 -1.25 TD
[(ANA)-220 (titer \(> 1:640\))-10447 (73)-10375 (61.30)-7400 (0.05)]TJ
0 Tw T*
[(ANA)-220 (pattern)]TJ
0.7 -1.25 Td
[(Homogeneous)-12024 (22)-11000 (20)-8025 (0.85)]TJ
T*
[(Speckled)-14135 (52)-11000 (44)-8025 (0.25)]TJ
0 Tc 0.02499 Tw T*
[(Nucleolar)-13858 (16)-11000 (34)-7605 (< 0.01)]TJ
0 Tw T*
[(Centromere)-13080 (15)-10375 (19.30)-7400 (0.42)]TJ
-0.00011 Tc 0.02499 Tw -0.7 -1.25 Td
[(Anti-Scl-70 \(+\))-11650 (12.50)-9750 (15.30)-7400 (0.44)]TJ
T*
[(Anticentromere \(+\))-10096 (20.50)-9750 (26.60)-7400 (0.23)]TJ
T*
[(ANA)-220 (\(+\), Scl-70 \(\320\), )55 (ACA)-220 (\(\320\))-5717 (47.90)-9750 (50.00)-7400 (0.54)]TJ
0 -2.5 TD
(* 4 patients in the SSc + cancer group did not have available autoantibo\
dy studies.)Tj
/T1_0 1 Tf
0 Tc 0.0215 Tw 0 -2.725 TD
[(T)92 (able 3. )]TJ
/T1_1 1 Tf
-0.00011 Tc 3.6955 0 Td
(Autoantibody patterns in SSc patients with cancer according to selected \
cancer sites. Data are given as)Tj
0 Tw -3.6955 -1.25 Td
(percentages.)Tj
0.02499 Tw 0 -2.5 TD
[(Cancer Site)-5726 (Anti-Scl-70 \(+\))-1098 (Anticentromere \(+\))-1132 (ANA)-220 (\(+\), Scl-70 \(\320\), )55 (ACA)-220 (\(\320\))-814 (ANA)-220 (\(+\))]TJ
0 -1.25 TD
(\(no. of patients\))Tj
0 -2.5 TD
[(Breast \(23\)*)-8255 (4)-7350 (26)-9475 (39.10)-7075 (65)]TJ
0 -1.25 TD
[(Lung \(10\))-8949 (30)-7100 (30)-10100 (40)-7450 (100)]TJ
T*
[(Oropharynx \(7\)**)-5728 (15)-7350 (0)-9725 (57.10)-7075 (86)]TJ
0 Tc T*
[(Esophageal \(7\))-6325 (14.70)-5850 (28.50)-8850 (57.10)-6825 (100)]TJ
-0.00011 Tc 6.7789 Tw T*
[(Non-Hodgkin\325)55 (s 0)-7600 (0)-10100 (100)-7200 (100)]TJ
0.02499 Tw T*
(lymphoma \(5\)***)Tj
T*
[(Ovarian \(4\))-8589 (0)-7350 (25)-10100 (25)-7700 (50)]TJ
0.0983 Tw 0 -2.5 TD
[(* One patient without available autoantibody studies. ** )18 (T)70 (wo patients without autoantibody studies. *** One)]TJ
0.02499 Tw 0 -1.25 TD
(patient without autoantibody studies.)Tj
ET
128 706 m
488 706 l
128 687 m
487 687 l
129 577 m
488 577 l
130 523 m
486 523 l
127 494 m
488 494 l
127 414 m
488 414 l
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
16 0 obj
<>stream
8;Z\78Wpt6%.+"DORGl&XVCsU>Hoi'V%Q+Nd*c*&b!lmi!9?:;f)K2(!Ja1+f,5VL
>N4Ea04P;E=f`B3VHmc]-PT*.YlmSTI[/H8?7E1ona.$M;U/N8])u3dYpZiGg4j!`
X_+trDT=IF/Yh^BFafU9?+5)4g*OjeRbWaMF?TJL=p*LU/6*i^qQ.l/#Mej%1j_g%
1dQt_JC'Bi(igJOY)3!A+:I;JZ+%!(6F.QF=r8Nj-MI\_0$B[kUS)TT)]_uOb(SkE
rTX!dA>>HVToG!0H3i.B+*&P;\\+i/:oHWM_:]:&VTrhKtpCug2)7''PMOm02"1rWZ1*U'47.lQkBLLUD)V8;e^VPO,[0tYXl"^
DSq0,VlR9p-]Chbp_m?[`0@"oZdXUGe7+isOSUl&p^.Z:;0133DIpfC>[-*c_<,^I
ir='aGG$#84>WuDl!<98Zp+j7Pa(U+M4j^[M%IiK]0iK9lhg/sM_\P?Y%?Y04qJJ>
*1$Y]%tMH)Q`rh;*#"\cHG5qbA]k]JkO-FO>.)`A)ld,ML37HF@q4O%er_.e+u.9P
[F71LmUrd$p_s2G=0Q3~>
endstream
endobj
20 0 obj
[/Indexed/DeviceRGB 255 19 0 R]
endobj
19 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
43 0 obj
<>
endobj
48 0 obj
<>
endobj
89 0 obj
<>
endobj
110 0 obj
<>
endobj
49 0 obj
<>
endobj
73 0 obj
<>stream
H|T TSW~KBER((n\iqAt0@$!!T ʪ//FA*] M#j;ZQtG/39홙w.a8xq٪Uo*S1f`lnAt[3R@Srk.[U9sLqVWW4djOd1IbySw
W&L)ےWeVS+#d^11wXL+u{Y뻽TzBSD(chflJO*e^kd
uBNbq0*BЩ_|ma<.fޣ6Za;aX0sc_kfffWMD&b<9i+'S(ޭiNӊ4}}ӿ1oF'e6iTV?yr3_ZG[
±Y*)kʛ-%1;|vV6ۦH6~3g_XiFH.\q5F@[#/6P-}vH0j7qxN]
G=r_ WY+
]
8:! YMunޭ{1UuYNdc c(2 P,Ӱ